Company profile

HAYA Therapeutics SA

HAYA Therapeutics is dedicated to treating heart failure through the discovery and development of innovative first-in-class RNA-based therapeutics, with a specific focus on long noncoding RNAs.

Source: startup.ch

Highlights

Innosuisse Certificate

Top 100 Swiss Startup Award 2024

Top 100 Swiss Startup Award 2023

Top 100 Swiss Startup Award 2022

Top 100 Swiss Startup Award 2021

Top 100 Swiss Startup Award 2020

More news about HAYA Therapeutics SA

08.05.2025 16:00

HAYA Therapeutics banks $65 million Series A funding

Financing

05.05.2025 10:00

Recognition for Swiss innovators across the globe

Award

17.03.2025 17:00

Seasoned executives join Swiss startups

Background

17.02.2025 15:00

Healthtech startups set for growth

Award

23.09.2024 10:40

Set for growth: startups rely on experienced leaders

Background

04.09.2024 15:27

HAYA Therapeutics wins Major Collaboration with Lilly

Success

23.07.2024 09:00

Erfahrene Expertinnen und Experten verstärken Startup-Management

Background

01.07.2024 11:50

Inaugural European entrepreneur award crowns HAYA Therapeutics Founders

Award

14.03.2024 14:00

Swiss Economic Awards: 9 Startups im Finale

Award

25.01.2024 14:35

ZKB Pionierpreis Technopark shortlists 11 startups

Award

07.09.2023 08:50

A biotech company ranks first at the TOP 100 Swiss Startup Award

Award

14.10.2022 09:30

International and seasoned board members for Switzerland

Expansion

10.02.2022 12:54

New US Laboratory and funding for HAYA Therapeutics

Financing

20.05.2021 10:45

HAYA Therapeutics closes CHF 18 million seed round

Financing

25.09.2020 10:15

Swissnex Boston welcomes 12 Swiss startups to its virtual Bootcamp

Expansion

Support

25.02.2020 08:46

A fruitful year for Business Angels Switzerland

Financing

19.09.2019 17:05

CHF 100.000 for Haya Therapeutics

Support

07.06.2019 13:08

>>venture>> announces nine winners

Award

15.05.2019 10:15

>>Venture>> finalists to contest for a cash prize of CHF 350000

Award

16.08.2018 13:57

CHF130’000 for startups with new heart failure and tissue reconstruction therapies

Award

04.06.2018 13:45

Boston: strong Swiss presence at the Swiss Biotech pavilion

Support

04.05.2018 10:35

Insights, announcements and a 3d concrete printer

Award

Support

27.11.2017 10:02

First companies selected for StartLab incubator

Support

17.11.2017 10:10

MassChallenge: 7 winners and a new food accelerator program

Award

04.10.2017 14:02

MassChallenge Switzerland announces the Top 12 startups

Award

24.05.2017 08:20

MassChallenge Switzerland Announces 2017 Class of Startups

Award

Founded
2019

Kanton
VD

Twitter
@HaYaTherapx

Homepage

Swiss Venture Capital Report TEST

The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". You can download it in our assets section.